Results from the study demonstrated that patients treated with TEGSEDI experienced early, sustained and highly significant benefit in both co-primary endpoints: the modified Neuropathy Impairment Score +7 (mNIS+7), a measure of neuropathic disease progression, and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN), compared to placebo-treated patients. Furthermore, a substantial number of TEGSEDI-treated patients displayed improvements in disease symptoms as measured in both co-primary endpoints, compared to their baseline study entry values. The clinical benefits demonstrated by TEGSEDI were associated with substantial reductions in the transthyretin (TTR) protein, the underlying cause of hATTR amyloidosis. For the full text of this publication, please visit: https://www.nejm.org/doi/full/10.1056/NEJMoa1716793.
"hATTR amyloidosis is a progressive, systemic and fatal disease that relentlessly deprives people of their independence and dignity. People with hATTR amyloidosis experience misfolded TTR build up in various tissues and organs, resulting in progressively debilitating symptoms which lead to death within a few years of symptom onset," said
"Based on these study results and the feedback we have received from physicians and patients, we believe TEGSEDI has the potential to provide people living with hATTR amyloidosis a greater degree of control over their disease and their lives together with the convenience of a once weekly, self-administered subcutaneous injection," said
"We believe the NEURO-TTR Phase 3 results demonstrate a favorable benefit-risk profile for TEGSEDI to treat patients with this devastating disease. Patients treated with TEGSEDI experienced substantial improvements in measures of neuropathy and quality of life compared to placebo-treated patients, independent of TTR mutation type, disease stage or presence of cardiomyopathy. Remarkably, half of the TEGSEDI-treated patients in this study experienced improvement in their quality of life over the course of their treatment and nearly 40% improved in a measure of neurological disease progression," said Brett P. Monia, Ph.D., chief operating officer, senior vice president of antisense drug discovery and translational medicine at Ionis Pharmaceuticals.
ABOUT NEURO-TTR: TEGSEDI PHASE 3 CLINICAL STUDY
The NEURO-TTR study was a Phase 3 randomized (2:1), double-blind, placebo-controlled, international study in 172 patients with polyneuropathy due to hATTR amyloidosis. The 15-month study measured the effects of treatment with TEGSEDI on neurological dysfunction and on quality-of-life by measuring the change from baseline both in the modified Neuropathy Impairment Score +7 (mNIS+7) and in the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QOL-DN) total score. The NEURO-TTR OLE is an ongoing study for patients who completed the NEURO-TTR study and is intended to evaluate the long-term efficacy and safety profile of TEGSEDI.
In the NEURO-TTR study, patients treated with TEGSEDI experienced benefit compared to placebo across both primary endpoints of the study: the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) and the modified Neuropathy Impairment Score +7 (mNIS+7) at both eight and 15 months of treatment. In addition, patients treated with TEGSEDI experienced significant benefit in both the Norfolk-QoL-DN and mNIS+7, independent of disease stage, types of mutation or presence of cardiomyopathy. Most TEGSEDI-treated patients experienced substantial reductions in TTR. Nearly 90% of patients achieved >50% TTR reduction and nearly 50% achieved over 75% TTR reduction at 15 months. Median TTR reduction was 79% at Week 65. These TTR reductions were associated with improvements from baseline in the Norfolk QoL-DN primary endpoint with a mean difference in magnitude of 11.68 points, compared to placebo-treated patients, at 15 months of treatment (mean change from baseline of 0.99 vs. 12.67, p<0.001). 50% of TEGSEDI-treated patients had improved Norfolk QoL scores compared to their baseline scores. Clinically meaningful benefit was also observed in TEGSEDI-treated patients compared to placebo-treated patients in the SF-36 physical component score, a measure of general health quality of life. In addition, TEGSEDI-treated patients benefited significantly in the co-primary endpoint assessing disease control, the mNIS+7, achieving a mean difference in magnitude of 19.73-points, compared to placebo-treated patients, at 15 months of treatment (mean change from baseline of 5.80 vs. 25.53, p<0.001). 36.5% of TEGSEDI-treated patients had improved mNIS+7 scores compared to their baseline scores. As previously reported, encouraging benefit was also observed in TEGSEDI-treated patients with significant cardiac disease at baseline (interventricular septum thickness, IVS ≥ 1.5 cm) in multiple cardiac measures, including mean decreases in left ventricle mass (p=0.0288), IVS (p=0.0150) and posterior wall thickness (p=0.0425), which increased, on average, in placebo-treated patients.
Thrombocytopenia and safety signals related to renal function were identified during the study. Enhanced monitoring was implemented during the study to support early detection and management of these issues. Serious platelet and renal events were infrequent and manageable with routine monitoring, which has proven effective since implementation.
Adverse events occurring in >=10% of patients and twice as frequently in TEGSEDI-treated patients compared with placebo-treated patients included thrombocytopenia/platelet count decreases, nausea, pyrexia, chills, vomiting, and anemia. Injection site reactions were observed in about 1% of all injections and were mild or moderate in severity. There were no discontinuations due to injection site reactions. There were five deaths in the study, five (4.5%) in the TEGSEDI arm and zero in the placebo arm. The mortality rate in the drug-treatment arm is comparable to the death rate expected in this patient population as evidenced in other clinical trials. Four deaths were associated with disease progression and considered unrelated to treatment. As previously reported, there was one fatal intracranial hemorrhage in conjunction with serious thrombocytopenia. No serious thrombocytopenia was observed following implementation of more frequent monitoring in the NEURO-TTR study.
ABOUT TEGSEDI (inotersen)
TEGSEDI™ (inotersen) is an antisense drug designed to reduce the production of transthyretin, or TTR protein, to treat ATTR amyloidosis, a systemic, progressive and fatal disease. TEGSEDI is currently under regulatory review for marketing approval in the U.S., EU and
ABOUT HEREDITARY ATTR (hATTR) AMYLOIDOSIS
hATTR amyloidosis is a progressive, systemic and fatal hereditary disease caused by the inappropriate formation and aggregation of TTR amyloid deposits in various tissues and organs throughout the body, including in peripheral nerves, heart, intestinal tract, eyes, kidneys, central nervous system, thyroid and bone marrow. The progressive accumulation of TTR amyloid deposits in these tissues and organs leads to sensory, motor and autonomic dysfunction often having debilitating effects on multiple aspects of a patient's life. People with hATTR amyloidosis often present with a mixed phenotype and experience overlapping symptoms of polyneuropathy and cardiomyopathy. People with hATTR with symptoms of polyneuropathy are classified into 3 stages: Stage 1 patients do not require assistance with ambulation, Stage 2 patients do require assistance with ambulation and Stage 3 patients are confined to a wheelchair or are bedridden.
Ultimately, hATTR amyloidosis results in death within three to fifteen years of symptom onset. Therapeutic options for the treatment of patients with hATTR amyloidosis are limited and there are currently no disease-modifying drugs approved for the disease. There are an estimated 50,000 patients with hATTR amyloidosis worldwide. Additional information on hATTR amyloidosis, including a full list of organizations supporting the hATTR amyloidosis community worldwide, is available at www.hattrchangethecourse.com.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over 40 drugs in development. SPINRAZA® (nusinersen) has been approved in global markets for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. TEGSEDI™ (inotersen) and WAYLIVRA (volanesorsen) are two antisense drugs that Ionis discovered and successfully advanced through Phase 3 studies. TEGSEDI is under regulatory review for marketing approval in the U.S., EU and
AKCEA'S AND IONIS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding the business of
In this press release, unless the context requires otherwise, "Ionis", "Akcea," "Company," "Companies" "we," "our," and "us" refers to
Ionis Pharmaceuticals™ is a trademark of
View original content with multimedia:http://www.prnewswire.com/news-releases/new-england-journal-of-medicine-publishes-results-from-pivotal-study-of-tegsedi-inotersen-for-the-treatment-of-hereditary-attr-amyloidosis-300676409.html
Akcea Media and Investor Contact: Kathleen Gallagher, Head of Communications and Investor Relations, (617)-207-8509, firstname.lastname@example.org, or Ionis Pharmaceuticals Investor Contact: D. Wade Walke, Ph.D., Vice President, Corporate Communications and Investor Relations, 760-603-2741, email@example.com, or Ionis Pharmaceuticals Media Contact: Roslyn Patterson, Vice President, Corporate Communications, 760-603-2681, firstname.lastname@example.org